Characterizing the Activation of the Wnt Signaling Pathway in Hilar Cholangiocarcinoma Using a Tissue Microarray Approach
Overview
Affiliations
Hilar cholangiocarcinoma (HCCA) is an invasive hepatic malignancy that is difficult to biopsy; therefore, novel markers of HCCA prognosis are needed. Here, the level of canonical Wnt activation in patients with HCCA, intrahepatic cholangiocarcinoma (IHCC), and congenital choledochal cysts (CCC) was compared to understand the role of Wnt signaling in HCCA. Pathology specimens from HCCA (n=129), IHCC (n=31), and CCC (n=45) patients were used to construct tissue microarrays. Wnt2, Wnt3, β-catenin, TCF4, c-Myc, and cyclin D1 were detected by immunohistochemistry. Parallel correlation analysis was used to analyze differences in protein levels between the HCCA, IHCC, and CCC groups. Univariate and multivariate analyses were used to determine independent predictors of successful resection and prognosis in the HCCA group. The protein levels of Wnt2, β-catenin, TCF4, c-Myc, and cyclin D1 were significantly higher in HCCA compared to IHHC or CCC. Wnt signaling activation (Wnt2+, Wnt3+, nuclear β-catenin+, nuclear TCF4+) was significantly greater in HCCA tissues than CCC tissues. Univariable analyses indicated that expression of cyclin D1 as well as Wnt signaling activation, and partial Wnt activation (Wnt2+ or Wnt3+ and nuclear β-catenin+ or nuclear TCF4+) predicted successful resection, but only cyclin D1 expression remained significant in multivariable analyses. Only partial Wnt activation was an independent predictor of survival time. Proteins in the canonical Wnt signaling pathway were present at higher levels in HCCA and correlated with tumor resecility and patient prognosis. These results suggest that Wnt pathway analysis may be a useful marker for clinical outcome in HCCA.
Systematic Review of Preoperative Prognostic Biomarkers in Perihilar Cholangiocarcinoma.
Pawaskar R, Huang K, Pham H, Nagrial A, Wong M, ONeill S Cancers (Basel). 2024; 16(4).
PMID: 38398089 PMC: 10886549. DOI: 10.3390/cancers16040698.
Philpose R, Mohammed A, Gowni A Pediatr Gastroenterol Hepatol Nutr. 2024; 27(1):62-70.
PMID: 38249641 PMC: 10796256. DOI: 10.5223/pghn.2024.27.1.62.
Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity.
Lozano E, Sanchon-Sanchez P, Morente-Carrasco A, Chinchilla-Tabora L, Mauriz J, Fernandez-Palanca P Cells. 2023; 12(8).
PMID: 37190050 PMC: 10136857. DOI: 10.3390/cells12081141.
Wnt signaling in liver regeneration, disease, and cancer.
Zou G, Park J Clin Mol Hepatol. 2022; 29(1):33-50.
PMID: 35785913 PMC: 9845677. DOI: 10.3350/cmh.2022.0058.
Selvaggi F, Catalano T, Cotellese R, Aceto G Cancers (Basel). 2022; 14(8).
PMID: 35454818 PMC: 9024538. DOI: 10.3390/cancers14081912.